Singapore

The Health Sciences Authority (HSA) is Singapore's primary regulatory body responsible for the evaluation, registration, and post-market surveillance of health products, including pharmaceuticals, medical devices, diagnostics, and digital health solutions. The principal governing legislation includes the Health Products Act (Cap. 122D) and its associated Health Products Regulations, which provide a unified, risk-based framework for regulating therapeutic products, medical devices, and health-related consumer products. Approval pathways vary by product category and risk classification: pharmaceuticals follow the Therapeutic Products registration route, while medical devices are registered under the Medical Devices Branch using a Class A to D risk classification system. HSA offers several expedited pathways, including the Innovative Medicines Access Programme (IMAP) and Priority Review for products addressing unmet medical needs, as well as a full reliance pathway leveraging decisions from reference agencies such as the US FDA, EMA, TGA, and Health Canada.

Key submission requirements include the appointment of a local registrant or Singapore-registered company as the product licence holder, which serves as the local responsible entity for regulatory correspondence and post-market obligations. Dossier submissions generally follow the Common Technical Document (CTD) format for pharmaceuticals and the ASEAN Common Technical Dossier (ACTD) format where applicable, with HSA also accepting submissions aligned with IMDRF guidelines for medical devices. Singapore actively participates in the ASEAN Medical Device Directive (AMDD) harmonisation framework and has deepened cooperation with international regulators through mutual recognition and information-sharing arrangements. Recent reforms include the expansion of the Provisional Authorisation scheme for digital health and Software as a Medical Device (SaMD), the introduction of a regulatory sandbox for novel health technologies, and enhanced guidance on AI-enabled medical devices, reflecting HSA's commitment to fostering health innovation while maintaining rigorous safety standards.

Public procurement of health products in Singapore is centralised and highly structured, operating primarily through the Ministry of Health (MOH) and its network of public healthcare institutions grouped into two main clusters: the National University Health System (NUHS) and the Singapore Health Services (SingHealth) cluster, with MOH Holdings (MOHH) serving as the holding entity overseeing public hospitals, polyclinics, and specialty centres. Centralised bulk tendering for pharmaceuticals and medical devices is coordinated through the Pharmaceuticals and Medical Devices department under MOH and MOHH, with framework agreements and standing contracts typically awarded through open competitive tenders on the Government Electronic Business (GeBIZ) platform. The Health Sciences Authority also plays a role in coordinating national stockpiles and essential medicine procurement. Public healthcare institutions are generally required to procure registered products and are bound by government procurement policies emphasising value-for-money, transparency, and accountability, with price negotiation playing a significant role in formulary listing decisions at both cluster and institution level.

The private healthcare sector in Singapore is substantial and commercially vibrant, encompassing private hospitals, specialist clinics, general practitioner networks, and retail pharmacy chains, all of which procure health products independently through distributors, direct manufacturer agreements, or group purchasing organisations. Singapore is a high-income country and is not a recipient of major donor-funded procurement programmes such as those administered by UNICEF Supply Division, the Global Fund, USAID, or Gavi; accordingly, these channels are not relevant to the Singapore market context. Singapore does not maintain explicit local manufacturing preference policies in public procurement, though the government actively supports the growth of its biomedical manufacturing sector through the Economic Development Board (EDB) and the Biomedical Sciences Industry Partnership Office, offering incentives for companies that establish local manufacturing or research and development operations. Singapore's status as a regional healthcare hub also means that successful market entry and regulatory approval in Singapore frequently serves as a reference point for broader ASEAN market access strategies.